Clario, a US-based provider of endpoint data solutions to the clinical trial industry, announced on Wednesday a multi-year agreement with Amazon Web Services (AWS) to advance its generative AI platform.

By leveraging AWS's AI and machine learning technologies, Clario said that it intends to enable healthcare and life sciences organisations to process complex documents and trial data with enhanced speed and accuracy, reducing clinical trial startup times.

According to Clario, its proprietary generative AI platform orchestrates multiple large language models and deep learning models using AWS infrastructure to achieve best in class results. This scalable system enables the rapid processing of clinical documents and multi-modal data, transforming vast volumes of unstructured information into actionable insights, empowering life sciences companies to accelerate innovation. By adopting an iterative approach to model development and optimising each phase of analysis, Clario said that it is delivering a scalable solution tailored to the unique challenges of clinical trials.

"We're excited to work with Clario to support the advancement of clinical trial data management using generative AI to analyse endpoint data across imaging, cardiac safety, eCOA and respiratory assessments," commented Allyson Fryhoff, AWS managing director of Healthcare & Life Sciences. "Their work underscores the huge opportunity that advanced technologies bring to drug development by transforming unstructured data into insights that help sponsors get effective therapies to patients faster than ever before."